New medicine for peripheral nerve pain! Mirogabalin was approved to treat peripheral neuropathic pain (..

Daiichi Sankyo, a Japanese pharmaceutical company, recently announced that Tarlige's 2.5mg, 5mg, 10mg and 15mg tablets had been approved by Japan for the treatment of peripheral neuropathic pain (PNP). In general, the initial dose in adult patients is 5 mg, 2 times daily orally, followed by a gradual increase of 5 mg at intervals of at least one week until 15 mg. The dose can be adjusted according to age and symptoms between 10 mg and 15 mg, 2 times a day orally.
Tarlige's active pharmaceutical ingredient is mirogabalin, an alpha-2 ligation created by the first three co-creations that, through oral administration, prioritize and selectively combine voltage-dependent calcium channels (1 and 2 The alpha-2-1 sub-units, but significantly more potency than pregabalin, these calcium channels are widely present in the nervous system in various areas of the body to mediat pain delivery and treatment, mirogabalin has a unique binding properties and long-lasting effect. Mirogabalin is in the same drug category as gabapentin and Pribarin.
first three submitted Tarlige's application for a new drug in February 2018, based on positive data from a Phase III clinical study conducted in patients with peripheral neuropathic pain (DPNP) diabetes and a Phase III clinical study in patients with post-herpes neuropathy (PHN). Both studies were conducted in Asia, including Japan.
, Tarlige is expected to provide patients and healthcare professionals in Japan with an innovative treatment for peripheral neuropathic pain (PNP). PNP is caused by peripheral nerve damage or functional abnormalities caused by a variety of causes, typically including diabetic PNP (DPNP) and post-herpes nerve pain (PHN).
DPNP and PHN are typical examples of PNP caused by nerve damage. DPNP is a disease that causes neuropathy and numbness in the limbs and is one of the three most common long-term complications of diabetes, with symptoms including severe pain, pain allergies, numbness, impaired balance and muscle movement, burning and tingling. Pain often worsens at night and can lead to sleep disorders. In Japan, it is estimated that there are more than 10 million people with diabetes, and 9-22% of patients report DPNP.
the onset of shingles is caused by a decrease in immunity to the chickenpox-belt sores virus, which forms latent infections in the nerve section. In PHN, burning pain or pain that penetrates the body like electricity persists even after the shingles have been cured, and the disease is considered a stubborn pain that can lead to muscle weakness and, in rare cases, paralysis. In Japan, between 500,000 and 600,000 people suffer from shingles each year, of whom 10-25% suffer from PHN. (Bio Valley)